On May 15, 2013, Bayer Healthcare Pharmaceuticals announced that it had received marketing approval for the therapeutic radioactive medication radium Ra 223 dichloride injection (Xofigo; Ra 223).
The product acquisition and distribution process for hospital-based nuclear pharmacies and nuclear medicine services is unlike any other. The product is distributed as a low-risk compounded sterile preparation through a single compounding nuclear pharmacy located in Denver, Colorado, pursuant to a prescription. This model for drug distribution and delivery to the user institution has implications for product quality, patient privacy, and delineation of professional responsibilities.
Written by:
Dansereau RN. Are you the author?
Albany Medical Center Hospital, Albany, NY, USA.
Reference: Ann Pharmacother. 2014 Nov;48(11):1512-4.
doi: 10.1177/1060028014545644
PubMed Abstract
PMID: 25301826